AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$WAY

Truist reiterates Waystar stock rating on strong bookings growth

Truist reiterated a Buy rating and $33.00 price target on Waystar (NASDAQ:WAY) after Q3 results. The company reported 10% organic revenue growth, 25% year-to-date bookings growth, and raised 2026 EBITDA guidance. Shares fell 7.4% in after-hours trading due to softer near-term revenue growth expectations.

Original reporting
investing.com
Published Nov 3, 2026, 9:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$WAY
Bearish
high confidence
Mentioned
$WAY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$WAYBearishHigh
01

Why it matters

The earnings beat is tempered by a lowered Q4 revenue outlook, leading to a notable after‑hours sell‑off.

02

Market read

Earnings release provides fresh guidance that can move the stock and influence sector peers.

03

What to watch

The return of a large academic medical center client and a 43% AI‑related booking share may drive future upside.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Waystar Holding (NASDAQ:WAY) released its third‑quarter 2026 earnings, highlighting organic revenue growth, high adjusted EBITDA margin, and increased AI product bookings.

Company-level read

Ticker impact

$WAYBearishHigh confidence
Context

Waystar reported Q3 2026 results with 21% revenue growth, $0.44 EPS and raised full‑year EBITDA guidance, but shares fell 7.4% after‑hours on softer Q4 outlook.

Expected impact

likely downside as the market prices in the softer Q4 revenue guidance

Evidence & confidence

The earnings beat is offset by a lowered Q4 growth outlook, causing a 7.4% after‑hours drop; traders may short or reduce exposure today.

Market effects

Sector

Healthcare services earnings may pressure peer valuations as guidance softness spreads.

Regional

U.S. small‑cap healthcare stocks could see modest pullback.

Global

Limited to U.S. markets; no direct global macro effect.

Counterpoint

What could challenge this read

Despite the after‑hours dip, the strong Q3 performance and AI‑driven bookings could support a rebound.

Key entities

  • company
    Waystar Holding

    U.S. healthcare revenue cycle management firm.

Read at source← All news

StoryWaystar posts Q3 revenue up 21% and issues lower‑than‑expected 2026 outlook

Also covered by

6 outlets

Related articles

NOV 3
$WAYHighAI 8/10

Why is Waystar stock sliding today?

Waystar Holding Corp (WAY) stock fell 4.1% in pre-market trading after Q3 earnings. Revenue rose 21% YoY to $325.6M, and adjusted EPS of $0.44 beat estimates. However, full-year 2026 revenue guidance missed expectations, with a midpoint of $1.282B below the $1.29B consensus. Analysts raised price targets but cited concerns over Q4 growth deceleration.

investing.com2 min
NOV 3
$WAYHighAI 8/10

Waystar Holding Corp (WAY) Q3 2026 Earnings Call Highlights: Revenue Jumps 21% as AI Bookings Surge

Waystar Holding Corp (WAY) reported Q3 2026 revenue growth of 21% YoY, with adjusted EBITDA up 24% and a 43% margin. Bookings surged 25% YoY, including a major client win. AI innovations drove 43% of Q3 bookings. However, Q4 revenue growth is expected to slow to ~6%, with adjusted EBITDA declining sequentially due to top-line variability and AI investments. Iodine's performance-based pricing model delayed revenue recognition. Net revenue retention was 108%, at the lower end of historical range.

finance.yahoo.com3 min
NOV 3
$WAYMed

Waystar: Q3 Earnings Snapshot

Waystar Holding Corp. (WAY) reported Q3 earnings of $31M, or 16 cents per share, beating estimates. Adjusted EPS was 44 cents. Revenue was $325.6M, also exceeding forecasts. The company expects full-year EPS of $1.63-$1.71 and revenue of $1.28B-$1.29B.

finance.yahoo.com2 min
NOV 3
$WAYHighAI 8/10

What Waystar (WAY) Said on Its Q3 Earnings Call

Waystar (WAY) reported Q3 bookings for Iodine exceeded year-to-date plans by 74%, with $15M in Q3 bookings. The company launched an autonomous claim-resubmission feature, estimating it could resubmit up to $5B in rejected claims annually. Waystar lowered its full-year revenue forecast to $1.277B-$1.287B but raised adjusted EBITDA guidance to $543M-$549M. The company cited timing pressures for the revenue outlook adjustment.

finance.yahoo.com2 min
NOV 2
$WAYHighAI 8/10

Waystar shares tumble 7% on weak fiscal 2026 guidance

Waystar Holding Corp (WAY) reported Q3 earnings of $0.44 per share, beating estimates, with revenue up 21% YoY to $325.6M. However, shares fell 7.3% on weak fiscal 2026 guidance, with projected EPS of $1.63-$1.71 and revenue of $1.277B-$1.287B, both below consensus. The company reported 10% net income margin and 43% adjusted EBITDA margin.

investing.com2 min